Functional role of RBM10 in lung adenocarcinoma proliferation

Sun,Xiuna; Jia,Mengqi; Sun,Wei; Feng,Lu; Gu,Chundong; Wu,Taihua

doi:10.3892/ijo.2018.4643

Functional role of RBM10 in lung adenocarcinoma proliferation

Authors:
- Xiuna Sun
- Mengqi Jia
- Wei Sun
- Lu Feng
- Chundong Gu
- Taihua Wu
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
Published online on: November 22, 2018 https://doi.org/10.3892/ijo.2018.4643
Pages: 467-478
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most common causes of morbidity and mortality among malignant tumors worldwide. The poor prognosis of patients with lung adenocarcinomas is primarily due to its strong ability to invade and metastasize. Recent research has indicated that RNA‑binding protein 10 (RBM10) is mutated in lung adenocarcinoma, and is closely associated with tumor proliferation and apoptosis; however, the precise role of RBM10 in lung adenocarcinoma remains unclear. Our preliminary experiments (unpublished data) revealed that RBM10 expression was upregulated in lung adenocarcinoma cell lines and tissues. In this study, we first detected the protein expression level of RBM10 in lung adenocarcinoma cells and tissues, and we then examined the effects of RBM10 overexpression and downregulation (via small interfering RNA) on the proliferation and apoptosis of stable lung adenocarcinoma cells, along with its possible mechanisms of action. We also used clinical samples of lung adenocarcinomas to verify our results. We found that RBM10 protein was overexpressed in lung adenocarcinoma cells and tissues, and it reduced p53 expression (as detected by immunofluorescence assay and western blot analysis) in A549 cells and inhibited apoptosis (as shown by flow cytometric assay). RBM10 also promoted cell growth and proliferation in vitro and increased cell migration in a cell wound scratch assay. Furthermore, we found that RBM10 activated key proliferative signaling pathways [such as the epidermal growth factor receptor (EGFR), mitogen‑activated protein kinase (MAPK) and phosphoinositide 3‑kinase (PI3K)‑AKT pathways] and inhibited apoptotic pathways. In addition, we demonstrated that a high expression of RBM10 protein in patient tissue samples was associated with a shorter overall survival time and a poor prognosis. On the whole, the findings of this study indicate that RBM10 may function as an oncogene in lung cancer, and may thus prove to be a novel therapeutic target for the prophylaxis and treatment of lung adenocarcinomas.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
2	Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, Beer DG, Cope L, Creighton CJ, Danilova L, et al: Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar
3	Ferlay J, Shin H-R, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
4	Mehlen P and Puisieux A: Metastasis: A question of life or death. Nat Rev Cancer. 6:449–458. 2006. View Article : Google Scholar
5	Milkovic L, Siems W, Siems R and Zarkovic N: Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr Pharm Des. 20:6529–6542. 2014. View Article : Google Scholar
6	Wee P and Wang Z: Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 9:3–45. 2017.
7	Milik SN, Lasheen DS, Serya RAT and Abouzid KAM: How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Eur J Med Chem. 7:1–21. 2017.
8	Zhao J, Sun Y, Huang Y, Song F, Huang Z, Bao Y, Zuo J, Saffen D, Shao Z, Liu W, et al: Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. Sci Rep. 7:404882017. View Article : Google Scholar
9	Vinayanuwattikun C, Le Calvez-Kelm F, Abedi-Ardekani B, Zaridze D, Mukeria A, Voegele C, Vallée M, Purnomosari D, Forey N, Durand G, et al: Elucidating genomic characteristics of lung cancer progression from in situ to invasive adenocarcinoma. Sci Rep. 6:316282016. View Article : Google Scholar
10	Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et al: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 6:67442015. View Article : Google Scholar
11	Rintala-Maki ND, Goard CA, Langdon CE, Wall VE, Traulsen KE, Morin CD, Bonin M and Sutherland LC: Expression of RBM5-related factors in primary breast tissue. J Cell Biochem. 100:1440–1458. 2007. View Article : Google Scholar
12	Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, et al: Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Reports. 15:857–865. 2016. View Article : Google Scholar
13	Jackson TC, Du L, Janesko-Feldman K, Vagni VA, Dezfulian C, Poloyac SM, Jackson EK, Clark RS and Kochanek PM: The nuclear splicing factor RNA binding motif 5 promotes caspase activation in human neuronal cells, and increases after traumatic brain injury in mice. J Cereb Blood Flow Metab. 35:655–666. 2015. View Article : Google Scholar :
14	Loiselle JJ and Sutherland LC: Differential downregulation of Rbm5 and Rbm10 during skeletal and cardiac differentiation. In Vitro Cell Dev Biol Anim. 50:331–339. 2014. View Article : Google Scholar
15	Rodor J, FitzPatrick DR, Eyras E and Cáceres JF: The RNA-binding landscape of RBM10 and its role in alternative splicing regulation in models of mouse early development. RNA Biol. 14:45–57. 2017. View Article : Google Scholar
16	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
17	Fulda S: Evasion of apoptosis as a cellular stress response in cell. Int J Cell Biol. 2:1–6. 2010.
18	Plati J, Bucur O and Khosravi-Far R: Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J Cell Biochem. 104:1124–1149. 2008. View Article : Google Scholar
19	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L; International Association for the Study of Lung Cancer International Staging Committee Participating Institutions: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar
20	Garrisi VM, Strippoli S, De Summa S, Pinto R, Perrone A, Guida G, Azzariti A, Guida M and Tommasi S: Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation. PLoS One. 9:e1120252014. View Article : Google Scholar
21	Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar
22	Bechara EG, Sebestyén E, Bernardis I, Eyras E and Valcárcel J: RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell. 52:720–733. 2013. View Article : Google Scholar
23	Wang K, Bacon ML, Tessier JJ, Rintala-Maki ND, Tang V and Sutherland LC: RBM10 modulates apoptosis and influences TNF-α gene expression. J Cell Death. 5:1–19. 2012. View Article : Google Scholar
24	Hernández J, Bechara E, Schlesinger D, Delgado J, Serrano L and Valcárcel J: Tumor suppressor properties of the splicing regulatory factor RBM10. RNA Biol. 13:466–472. 2016. View Article : Google Scholar
25	Julie J, Loiselle 1, Justin Roy G and Leslie C: Sutherland: RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. PLoS One. 12:1–23. 2017.
26	Tessier SJ, Loiselle JJ, McBain A, Pullen C, Koenderink BW, Roy JG and Sutherland LC: Insight into the role of alternative splicing within the RBM10v1 exon 10 tandem donor site. BMC Res Notes. 8:462015. View Article : Google Scholar
27	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar
28	Martín-Garabato E, Martínez-Arribas F, Pollán M, Lucas AR, Sánchez J and Schneider J: The small variant of the apoptosis-associated X-chromosome RBM10 gene is co-expressed with caspase-3 in breast cancer. Cancer Genomics Proteomics. 5:169–173. 2008.
29	Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF and Hung MC: Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 65:338–348. 2005.
30	Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D and Burtness BA: Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 11:5856–5862. 2005. View Article : Google Scholar
31	Xiao SJ, Wang LY, Kimura M, Kojima H, Kunimoto H, Nishiumi F, Yamamoto N, Nishio K, Fujimoto S, Kato T, et al: S11/RBM10: Multiplicity and cooperativity of nuclear localisation domains. Biol Cell. 105:162–174. 2013. View Article : Google Scholar
32	Dvinge H, Kim E, Abdel-Wahab O and Bradley RK: RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 16:413–430. 2016. View Article : Google Scholar :
33	Inoue A, Yamamoto N, Kimura M, Nishio K, Yamane H and Nakajima K: RBM10 regulates alternative splicing. FEBS Lett. 588:942–947. 2014. View Article : Google Scholar
34	Lukong KE, Chang KW, Khandjian EW and Richard S: RNA-binding proteins in human genetic disease. Trends Genet. 24:416–425. 2008. View Article : Google Scholar : PubMed/NCBI
35	Ozuemba B, Masilamani TJ, Loiselle JJ, Koenderink B, Vanderbeck KA, Knee J, Larivière C and Sutherland LC: Co- and post-transcriptional regulation of Rbm5 and Rbm10 in mouse cells as evidenced by tissue-specific, developmental and disease-associated variation of splice variant and protein expression levels. Gene. 580:26–36. 2016. View Article : Google Scholar
36	Johnston JJ, Sapp JC, Curry C, Horton M, Leon E, Cusmano-Ozog K, Dobyns WB, Hudgins L, Zackai E and Biesecker LG: Expansion of the TARP syndrome phenotype associated with de novo mutations and mosaicism. Am J Med Genet A. 164A:120–128. 2014. View Article : Google Scholar
37	Angeloni D: Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. Brief Funct Genomics Proteomics. 6:19–39. 2007. View Article : Google Scholar
38	Martínez-Arribas F, Agudo D, Pollán M, Gómez-Esquer F, Díaz-Gil G, Lucas R and Schneider J: Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer. J Cell Biochem. 97:1275–1282. 2006. View Article : Google Scholar
39	Sutherland LC: RNA binding motif (RBM) proteins: A novel family of apoptosis modulators? J Cell Biochem. 94:5–24. 2005. View Article : Google Scholar